The FDA launched AEMS, a unified platform that replaces fragmented legacy databases to enable real-time adverse event reporting.
In a recent interview, Jay Bregman, founder and CEO of Andel, discussed his company's newly launched direct-to-employer medication platform, which is designed to reduce prescription drug costs by ...
In today's Pharma Pulse, the NCPA warns of a severe cash flow crisis for independent pharmacies under the Medicare Drug Price ...
In today's Pharma Pulse, Ipsen voluntarily withdraws tazemetostat due to safety signals, while the FDA approves deucravacitinib for active psoriatic arthritis.
Demographic, regulatory, and geopolitical pressures compound SM-to-CGT portfolio diversification, adding short lifecycles, ultra-cold logistics, patient-window ...
Agreement enables Hims & Hers users to access branded Ozempic 0.5–2 mg and Wegovy injectable 0.25–2.4 mg plus oral strengths 1.5–25 mg. Hims & Hers will cease marketing compounded GLP-1 products and ...
Section 804 creates a legal pathway for states and tribes to import certain Canadian prescription drugs, contingent on demonstrable consumer savings and adherence to FDA public health safeguards. Cost ...
In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while ...
A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity ...
The Inflation Reduction Act (IRA) of 2022 introduced sweeping changes to the US prescription drug market, most notably ...
In today’s Pharma Pulse, Eli Lilly has launched the Employer Connect platform broadening access to Zepbound for U.S. workers, while Tandem Diabetes expands the reach of its Mobi insulin pump to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results